Log in with your email address username.


[Correspondence] Are new technologies translatable to point-of-care testing?

The point-of-care testing (PoCT) market is rapidly expanding and its predicted worth by 2021 is US$36·96 billion.1 This market has many facets, one of which is tumour and cancer markers. To develop a new test for clinical use, a biomarker needs to be identified and a quick and simple detection method developed. This biomarker then goes through many steps before clinical use including the all-important step—can it detect cancer earlier than existing methods?